On July 23, 2026, the company received a Nasdaq deficiency letter after its common stock closed below the $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1). Invivyd has until January 19, 2027 to regain compliance by maintaining a closing bid of at le…
Invivyd Price Target Maintained With a $10.00/Share by BTIG
Shares of Invivyd (IVVD) fell 6% on Monday after the company announced that it has received notice from the U.S. Food and Drug Administration (FDA) of the impending expiry of the emergency use authorization for its PEMGARDA preventive treatmentPEMGARDA’s emergency status will end on June 29, 2027…
Invivyd received FDA notice that PEMGARDA's EUA will terminate on June 29, 2027, after a 12-month transition following HHS's EUA declaration termination notice.Key Highlights:Original SEC Filing: Invivyd, Inc. [ IVVD ] - 8-K - Jul. 06, 2026This is an AI-powered summary. It may contain inaccuracies…
NEW HAVEN, Conn., July 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. NASDAQ:IVVD today announced that on July 1, 2026, Invivyd granted 14 newly hired non-executive employees options to purchase an aggregate of 493,000 shares of its common stock, each as a material inducement for each employee’s entry…
ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences NASDAQ:NBP (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the appointment of Srishti Gupta, MD MPP as Chief Execu…
